Company Overview
Decoy Therapeutics Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it seeks to advance peptide conjugate therapeutics. The company utilizes its proprietary Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology, known as the IMP3ACT platform, which is designed to reduce the inherent complexity associated with drug development and manufacturing processes. This platform leverages machine learning and artificial intelligence to streamline the creation of therapeutic agents. The company currently maintains a market capitalization of $3.35M and employs a workforce of 2 individuals. These financial metrics and operational scale indicate that Decoy Therapeutics is a micro-cap entity with very limited revenue generation and a minimal operational footprint, positioning it as a highly speculative asset in the biotechnology landscape rather than an established commercial player.
Financial Health
The company reports no revenue for the trailing twelve months, a net income of $-5,563,679, and an EBITDA of $-5,563,679, reflecting the significant burn rate typical of early-stage biotechnology firms. The complete absence of revenue combined with substantial negative net income reveals a cost structure dominated by research and development expenses that far exceed any current income generation. The company holds $4.81M in cash reserves while reporting negative free cash flow of $-2,818,466, which indicates a consumption of capital that limits immediate financial flexibility but provides a runway for ongoing operations. All three margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that signifies the company is not yet profitable and that costs are consuming the entirety of its theoretical revenue potential. Although the company has no debt, the debt-to-equity ratio is listed as N/A, and the balance sheet relies entirely on its cash position to fund operations without leverage. The current ratio stands at 3.28, suggesting that the company possesses sufficient liquid assets to cover its short-term liabilities, though this liquidity is finite given the negative cash flow trajectory. Return on Equity is -139.6% and Return on Assets is -69.9%, metrics that reveal management is currently destroying shareholder value through operational losses rather than generating returns on the capital deployed.
Valuation Assessment
The trailing P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -0.49, a negative figure that implies the market is pricing in future profitability or that the current valuation model relies on non-earnings-based metrics. The price-to-book ratio is 0.12, indicating that the market values the company's equity at a fraction of its book value, which is common for pre-revenue biotechnology companies but suggests a lack of market premium over tangible assets. The price-to-sales ratio is N/A and the EV/EBITDA is 0.31; these alternative valuation metrics suggest that traditional multiples are inapplicable, and the valuation is driven by the potential of the underlying technology rather than current financial performance. The stock has traded between a 52-week low of $6.18 and a 52-week high of $415.80, illustrating extreme price volatility and a wide range of market sentiment regarding the asset's potential. The beta value is 0.32, which indicates that the stock's price volatility is significantly lower than the broader market, though this low beta may be distorted by the company's micro-cap status and lack of liquidity.
Growth & Income
Revenue growth and earnings growth rates are both N/A for the year-over-year period, as the company has not generated revenue to calculate meaningful growth percentages. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company reinvests all available cash flow back into research, development, and platform advancement rather than distributing income to shareholders. The overall growth and income profile is characterized by zero current income generation and a reliance on capital markets or cash reserves to fund future growth initiatives.